拜玛林制药(BMRN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BMRN 拜玛林制药

盘前交易 07-17 07:39:33 EDT

85.89

+1.30

+1.54%

最高85.92	最低84.73	成交量109.85万
今开85.17	昨收84.59	日振幅1.41%
总市值163.09亿	流通市值161.80亿	总股本1.90亿
成交额9,391万	换手率0.58%	流通股本1.88亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"BMRN","market":"US","secType":"STK","nameCN":"拜玛林制药","latestPrice":85.89,"timestamp":1721160000000,"preClose":84.59,"halted":0,"volume":1098454,"delay":0,"floatShares":188380189,"shares":189879803,"eps":1.070064,"marketStatus":"盘前交易","marketStatusCode":1,"change":1.3,"latestTime":"07-17 07:39:33 EDT","open":85.17,"high":85.92,"low":84.73,"amount":93905437.42342,"amplitude":0.014068,"askPrice":85.89,"askSize":5,"bidPrice":78.79,"bidSize":17,"shortable":3,"etf":0,"ttmEps":1.070064,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721223000000},"adr":0,"listingDate":932702400000,"adjPreClose":85.89,"adrRate":0,"postHourTrading":{"tag":"盘后","latestPrice":85.89,"preClose":85.89,"latestTime":"19:03 EDT","volume":40610,"amount":3487992.9017,"timestamp":1721170980811},"volumeRatio":0.9018950030157012,"optionData":{"bulkOrders":[{"symbol":"BMRN","call":true,"expireDate":1723780800000,"strike":"90.0","timestamp":1721139953959,"price":1.399999976158142,"volume":1486,"amount":208040,"type":"*"}]},"impliedVol":0.3226,"impliedVolPercentile":0.6135},"requestUrl":"/m/hq/s/BMRN/wiki","defaultTab":"wiki","newsList":[{"id":"2440238766","title":"BUZZ-BridgeBio公司在遗传病治疗中期试验中取得积极进展，业绩攀升","url":"https://stock-news.laohu8.com/highlight/detail?id=2440238766","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440238766?lang=zh_cn&edition=full","pubTime":"2024-06-04 21:13","pubTimestamp":1717506790,"startTime":"0","endTime":"0","summary":"    6月4日 - ** 药物开发商BridgeBio Pharma   股价盘前上涨8%至31.29美元** 该公司称，其口服疗法 infigratinib 在一项中期试验中显示， ，软骨发育不全患者的身体比例有了显著改善。** 软骨发育症是一种遗传性骨骼生长障碍，会导致短肢侏儒症** BMO Capital Markets分析师认为，这些数据表明，infigratinib的后期试验数据很可能与BioMarin Pharmaceutical公司的  软骨发育不全药物Voxzogo相当或更胜一筹。** 截至上日收盘，股价累计下跌28.2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","BK4139","BK4588","BBIO","BK4585","BMRN","IE0002270589.USD","BK4566","BK4505","IE00B7SZLL34.SGD","BUZZ","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2436992749","title":"美国研究综述-Bath & Body Works、Under Armour、Viking Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2436992749","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436992749?lang=zh_cn&edition=full","pubTime":"2024-05-17 18:51","pubTimestamp":1715943108,"startTime":"0","endTime":"0","summary":"    路透5月17日 - 华尔街证券分析师周五调整了对几家美国上市公司的评级和目标价，其中包括 Bath & Body Works、Under Armour 和 Viking Therapeutics。要闻  * Advanced Drainage Systems Inc   ：巴克莱将目标价从189美元上调至202美元             * Bath & Body Works Inc   ：摩根大通将其评级从 \"减持 \"上调至 \"中性\"。* Under Armour Inc   ：摩根大通将其评级从 \"中性 \"下调至 \"减持\"。* Viking Therapeutics Inc   ：Raymond James将其评级从 \"跑赢大盘 \"上调至 \"强力买入\"。* Abbvie Inc   ：Cantor Fitzgerald给予该公司 \"增持 \"评级，目标价200美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSCO","AMTX","ABBV","BK4109","BK4589","LENZ","OBDC","CSWC","DE","FOLD","CFG","WMS","FOR","ANF","AZPN","LU0029864427.USD","APLS","ARRY","LU0823411888.USD","HEI","UA","ACHR","CBRL","CPRT","DHI","COGT","AN","DOCS","BAC","BKKT","BK4227","LU1291159041.SGD","BBWI","FLO","IE00BLSP4452.SGD","AMAT","FCNCA","CPAY","CCL","CVI","BK4134","HLT","BURL","BMRN","DD","LU0348723411.USD","DXC","GPI","LU0208291251.USD","COIN"],"gpt_icon":0},{"id":"2436999412","title":"Baird：下调Biomarin Pharmaceutical(BMRN.US)评级，由优于大市调整至中性评级, 目标价由104.00美元调整至72.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2436999412","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436999412?lang=zh_cn&edition=full","pubTime":"2024-05-17 17:25","pubTimestamp":1715937959,"startTime":"0","endTime":"0","summary":"Baird：下调Biomarin Pharmaceutical(BMRN.US)评级，由优于大市调整至中性评级, 目标价由104.00美元调整至72.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405171726008b1208b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405171726008b1208b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BMRN"],"gpt_icon":0},{"id":"2435568188","title":"美国研究综述-Akoya Biosciences、波士顿啤酒公司、胜利资本控股公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2435568188","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435568188?lang=zh_cn&edition=full","pubTime":"2024-05-14 15:22","pubTimestamp":1715671336,"startTime":"0","endTime":"0","summary":"    路透5月14日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价，其中包括 Akoya Biosciences、波士顿啤酒公司和 Victory Capital Holdings。要点              * Akoya Biosciences Inc   ：Canaccord Genuity将目标价从10美元下调至6美元              * 波士顿啤酒公司   ：杰富瑞将目标价从335美元上调至360美元             * Fortrea Holdings Inc   ：Evercore ISI将目标价从43美元下调至31美元              * Medical Properties Trust Inc   ：加拿大皇家银行将其评级从 \"跑赢大盘 \"下调至 \"行业表现\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","VCTR","BHF","BK4568","SG9999003800.SGD","CMPX","ARIS","NBIX","BK4551","BK4096","CDNA","JXN","EMR","BK4120","CIVB","FIVE","STZ","CHUY","MRNA","SG9999011175.SGD","BMRN","BBIO","MSGE","AKYA","NNI","LOB","NOTV","GPRE","IOVA","ATLC","FULC","NHI","BK4566","SAM","LU2249611893.SGD","AGL","CTRE","APDN","OBDC","JELD","MPW","BK4135","LEGN","BK4121","DH","BK4583","FTRE","BK4007","ACLX","BK4203"],"gpt_icon":0},{"id":"2430399282","title":"拜玛林制药2024财年第一财季实现净利润88.66百万美元，同比增加74.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430399282","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430399282?lang=zh_cn&edition=full","pubTime":"2024-04-26 00:19","pubTimestamp":1714061959,"startTime":"0","endTime":"0","summary":"3月31日，拜玛林制药公布财报，公告显示公司2024财年第一财季净利润为88.66百万美元，同比增加74.36%；其中营业收入为6.49亿美元，同比增加9.44%，每股基本收益为0.47美元。从资产负债表来看，拜玛林制药总负债17.99亿美元，其中短期债务4.94亿美元，资产负债比为3.83，流动比率为2.75。机构评级：截至2024年3月31日，当前有25家机构对拜玛林制药目标价做出预测，其中目标均价为110.23美元，其中最低目标价为80.00美元，最高目标价为140.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404260019258b53b3bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404260019258b53b3bb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BMRN"],"gpt_icon":0},{"id":"2430280307","title":"BUZZ-BioMarin 在第一季度收入不及预期后下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2430280307","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430280307?lang=zh_cn&edition=full","pubTime":"2024-04-25 23:03","pubTimestamp":1714057381,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    4月25日 - ** 制药公司 BioMarin Pharmaceutical    股价下跌 ~10.8% 至 81.35 美元** 周三收盘后，该公司公布的 (link) 第一季度营收为 6.488 亿美元，低于分析师平均预期的 6.518 亿美元 - LSEG 数据** BMRN 季度利润为每小时 71 美分，分析师平均预期为每小时 34 美分。** 包括本交易日的走势在内，该股今年累计下跌约 15.8%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B7SZLL34.SGD","IE0002270589.USD","BUZZ","BMRN","IE00B19Z3B42.SGD","BK4566","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2430285852","title":"拜玛林制药盘中异动 大幅跳水6.36%报85.40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430285852","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430285852?lang=zh_cn&edition=full","pubTime":"2024-04-25 21:32","pubTimestamp":1714051944,"startTime":"0","endTime":"0","summary":"北京时间2024年04月25日21时32分，拜玛林制药股票出现波动，股价快速下跌6.36%。截至发稿，该股报85.40美元/股，成交量41.73万股，换手率0.22%，振幅4.14%。最近的财报数据显示，该股实现营业收入24.19亿美元，净利润1.68亿美元，每股收益0.89美元，毛利18.42亿美元，市盈率98.16倍。拜玛林制药股票所在的生物技术行业中，整体跌幅为0.50%。拜玛林制药公司简介：BioMarin的重点是罕见疾病的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042521322487af68cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042521322487af68cd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B7SZLL34.SGD","BK4566","IE0002270589.USD","BK4139","IE00B19Z3B42.SGD","IE00B19Z3581.USD","BMRN"],"gpt_icon":0},{"id":"2429014509","title":"Biomarin Pharmaceutical Inc   预计每股收益35美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2429014509","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429014509?lang=zh_cn&edition=full","pubTime":"2024-04-23 05:20","pubTimestamp":1713820811,"startTime":"0","endTime":"0","summary":"   * Biomarin Pharmaceutical Inc    将于4月24日公布截至2024年3月31日的财报，预计该公司的季度收入将有所增长。* 根据LSEG的数据，22位分析师的平均预期显示，这家总部位于加利福尼亚州诺瓦托的公司的营收将从去年同期的5.9642亿美元增长9.3%，达到6.51788亿美元。* LSEG 分析师对 Biomarin Pharmaceutical Inc 的平均预期为每股收益 35 美分。* 华尔街对 Biomarin Pharmaceutical Inc 的 12 个月目标价中位数为 110.00 美元，高于其最新收盘价 88.63 美元。4月22日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMRN"],"gpt_icon":0},{"id":"2422535118","title":"维升药业三冲港交所IPO：增高针数据不及竞品前景待考","url":"https://stock-news.laohu8.com/highlight/detail?id=2422535118","media":"华尔街见闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2422535118?lang=zh_cn&edition=full","pubTime":"2024-03-25 09:50","pubTimestamp":1711331414,"startTime":"0","endTime":"0","summary":"失之毫厘，差之千里？","market":"hk","thumbnail":"https://wpimg-wscn.awtmt.com/content_default_5.jpg","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/content_default_5.jpg"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3711208","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3711208","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["CNP","LU0889565916.HKD","IE00BD4GTW91.USD","LU0109394709.USD","BK4139","IE00B7SZLL34.SGD","IE0002270589.USD","BK4588","IE00BD4GTV84.USD","IE00BD4GTT62.SGD","IE00B19Z3581.USD","BK4208","BMRN","IE00B19Z3B42.SGD","ASND","BK4566","LU0320765992.SGD","BK4585"],"gpt_icon":0},{"id":"2414851810","title":"更新版 1-BioMarin Pharma 收到司法部传票，内容涉及两种疗法的赞助测试计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2414851810","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2414851810?lang=zh_cn&edition=full","pubTime":"2024-02-27 03:36","pubTimestamp":1708976194,"startTime":"0","endTime":"0","summary":"     路透社2月26日 - BioMarin Pharmaceutical   在周一提交的一份文件中称， 已收到美国司法部的传票，要求提供该公司赞助的与两种治疗方法有关的测试项目的信息。BioMarin表示，司法部要求该公司提交与赞助测试其疗法Vimizim和Naglazyme有关的某些文件。Vimizim 是一种酶替代疗法，已被批准用于治疗 Morquio A 综合征，这是一种影响主要器官系统的罕见遗传性疾病。BioMarin 的另一种疗法 Naglazyme 获准用于治疗一种遗传性疾病--粘多糖病 VI。司法部没有立即回应路透社的置评请求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","IE00B19Z3B42.SGD","BK4566","IE00B7SZLL34.SGD","BMRN","IE0002270589.USD","BK4139"],"gpt_icon":0},{"id":"2414859316","title":"生物梅林制药公司收到司法部关于某些药物测试项目的传票","url":"https://stock-news.laohu8.com/highlight/detail?id=2414859316","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2414859316?lang=zh_cn&edition=full","pubTime":"2024-02-27 03:12","pubTimestamp":1708974772,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透社2月26日 - BioMarin制药公司  在周一提交的一份文件中说，该公司收到了美国司法部的传票，要求提供该公司赞助的与两种治疗方法有关的测试项目的信息。BioMarin没有立即回应路透社寻求更多信息的请求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","BMRN","IE00B19Z3581.USD","IE0002270589.USD","BK4139"],"gpt_icon":0},{"id":"2414099051","title":"拜玛林制药2023财年实现净利润1.68亿美元，同比增加18.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2414099051","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2414099051?lang=zh_cn&edition=full","pubTime":"2024-02-26 00:23","pubTimestamp":1708878233,"startTime":"0","endTime":"0","summary":"12月31日，拜玛林制药公布财报，公告显示公司2023财年净利润为1.68亿美元，同比增加18.31%；其中营业收入为24.19亿美元，同比增加18.17%，每股基本收益为0.89美元。从资产负债表来看，拜玛林制药总负债18.90亿美元，其中短期债务4.94亿美元，资产负债比为3.63，流动比率为2.52。机构评级：截至2023年12月31日，当前有25家机构对拜玛林制药目标价做出预测，其中目标均价为110.03美元，其中最低目标价为80.00美元，最高目标价为140.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022600240181b608d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022600240181b608d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BMRN"],"gpt_icon":0},{"id":"2413794808","title":"BUZZ-第四季度收入超预期，BioMarin 业绩攀升","url":"https://stock-news.laohu8.com/highlight/detail?id=2413794808","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2413794808?lang=zh_cn&edition=full","pubTime":"2024-02-24 01:00","pubTimestamp":1708707654,"startTime":"0","endTime":"0","summary":"    2月23日 - ** 疗法开发商 BioMarin Pharmaceutical    股价上涨 ~1% 至 90.87 美元** 公司季度收入为 6 .462 亿美元 ，超过分析师平均预期的 6.369 亿美元 - LSEG 数据     ** 该公司称其侏儒症疗法 Voxzogo 的收入  比上一季度增长了 18%，这主要是受美国 5 岁以下儿童处方量增加的积极影响。** TD Cowen 分析师表示，他们希望 BMRN 的收入增长加上成本控制将推动其股价达到 125 美元的目标价。** 包括本交易日的走势在内，该股在过去12个月中下跌了11.8%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7SZLL34.SGD","BK4566","BMRN","IE0002270589.USD","BUZZ","BK4139","IE00B19Z3581.USD","IE00B19Z3B42.SGD"],"gpt_icon":0},{"id":"2413273894","title":"美国研究综述-Biomarin Pharmaceutical、Intuit、Penumbra","url":"https://stock-news.laohu8.com/highlight/detail?id=2413273894","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2413273894?lang=zh_cn&edition=full","pubTime":"2024-02-23 15:28","pubTimestamp":1708673314,"startTime":"0","endTime":"0","summary":"    路透社2月23日 - 华尔街证券分析师周五调整了对几家美国上市公司的评级和目标价，其中包括 Biomarin Pharmaceutical、Intuit 和 Penumbra。要闻             * Biomarin Pharmaceutical Inc   ：Piper Sandler将目标价从115美元下调至107美元             * Intuit Inc   ：Susquehanna将目标价从700美元上调至775美元             * Penumbra Inc   ：摩根大通将其评级从 \"增持 \"下调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRTC","JPM","LU1815336091.USD","LU2125909247.SGD","IE00B19Z3B42.SGD","LU0211331839.USD","LU2089284900.SGD","FND","IE0034235188.USD","BK4209","KYMR","BK4082","LAW","LU0889565833.HKD","BK4122","GH","CHUY","LU0320765646.SGD","ENV","LU0511384066.AUD","NBIX","ALTR","ARQT","SQ","GB00BDT5M118.USD","LU0211328371.USD","PLNT","PODD","BMRN","BRDG","BK4567","IE00B3S45H60.SGD","BK4007","IDYA","LU1861559042.SGD","VIR","COLL","AGIO","PEN","ALRM","TPIC","ARDX","IE00B775SV38.USD","LU2089283258.USD","BK4178","CRI","BK4202","INTU","W","FIS"],"gpt_icon":0},{"id":"2413204955","title":"Biomarin Pharmaceutical Inc 公布截至 12 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2413204955","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2413204955?lang=zh_cn&edition=full","pubTime":"2024-02-23 11:15","pubTimestamp":1708658158,"startTime":"0","endTime":"0","summary":"   * Biomarin Pharmaceutical Inc   公布的截至12月底的季度调整后每股收益为18美分，高于去年同期的每股盈亏平衡收益。25 位分析师对该季度的平均预期是每股收益 23 美分。华尔街预期为每股收益 11 美分至 39 美分。* Biomarin Pharmaceutical Inc公布的本季度每股收益为11美分。* 该公司报告的季度净收入为2038万美元。* Biomarin Pharmaceutical Inc 本季度股价下跌了 8.2%。华尔街对 Biomarin Pharmaceutical Inc 的 12 个月目标价中位数为 109.95 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","BK4139","IE0002270589.USD","BMRN","BK4566","IE00B7SZLL34.SGD","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2406720792","title":"美国研究综述-Amerant Bancorp、陶氏、Humana","url":"https://stock-news.laohu8.com/highlight/detail?id=2406720792","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2406720792?lang=zh_cn&edition=full","pubTime":"2024-01-26 23:45","pubTimestamp":1706283921,"startTime":"0","endTime":"0","summary":"    路透1月26日 - 华尔街证券分析师周五调整了对几家美国上市公司的评级和目标价，其中包括 Amerant Bancorp、陶氏和 Humana。要闻 * Amerant Bancorp Inc   ：Piper Sandler将其评级从 \"增持 \"下调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAH","BFH","BSX","COF","ASB","BMY","COIN","BWB","CCCC","CLBK","LU1670710661.SGD","AVTR","LU1670710588.SGD","V","LU1670711123.USD","BX","AJG","AMP","ALB","ALK","APPF","BKR","SKIN","LU0310800965.SGD","LU0971096721.USD","ALPN","BYD","BBWI","AMD","CNX","LU1363072403.SGD","ABT","COLB","GOOGL","APH","LU0795875169.SGD","CNS","CATY","ALGN","LU0289961442.SGD","BMRN","AMGN","BRO","AMTB","ABBV","AAL","BANC","BIIB","BK4195","LU"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bmrn.com","stockEarnings":[{"period":"1week","weight":0.0351},{"period":"1month","weight":0.0285},{"period":"3month","weight":-0.0506},{"period":"6month","weight":-0.0718},{"period":"1year","weight":-0.009},{"period":"ytd","weight":-0.1092}],"compareEarnings":[{"period":"1week","weight":0.0163},{"period":"1month","weight":0.0407},{"period":"3month","weight":0.1285},{"period":"6month","weight":0.1855},{"period":"1year","weight":0.2529},{"period":"ytd","weight":0.1884}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Biomarin Pharmaceutical Inc.位于特拉华州，研发生产创新生物技术药物，治疗严重的疾病和健康问题。拜玛琳公司选择候选产品时，选择还未解决的具有重大意义的疾病和问题，对生物学有充分的认识，有机会率先面市或者使现有产品得到重大改进。公司产品组合包括四项定型产品和多项临床试验的候选产品。公司的定型产品分别是Naglazyme（加硫酶），Kuvan（二盐酸沙丙蝶呤），Firdapse（药磷酸阿米吡啶）和Aldurazyme（拉罗尼酶）。公司于1996年在特拉华州注册，于1997年3月21号运营。","yearOnYearQuotes":[{"month":1,"riseRate":0.68,"avgChangeRate":0.053118},{"month":2,"riseRate":0.44,"avgChangeRate":0.00883},{"month":3,"riseRate":0.48,"avgChangeRate":0.00524},{"month":4,"riseRate":0.52,"avgChangeRate":-0.015671},{"month":5,"riseRate":0.52,"avgChangeRate":0.009961},{"month":6,"riseRate":0.64,"avgChangeRate":0.01979},{"month":7,"riseRate":0.64,"avgChangeRate":0.039769},{"month":8,"riseRate":0.52,"avgChangeRate":-0.001402},{"month":9,"riseRate":0.48,"avgChangeRate":-0.001794},{"month":10,"riseRate":0.44,"avgChangeRate":-0.025565},{"month":11,"riseRate":0.8,"avgChangeRate":0.064297},{"month":12,"riseRate":0.64,"avgChangeRate":0.034986}],"exchange":"NASDAQ","name":"拜玛林制药","nameEN":"Biomarin Pharmaceutical"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.0","shortVersion":"4.25.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"拜玛林制药(BMRN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供拜玛林制药(BMRN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"拜玛林制药,BMRN,拜玛林制药股票,拜玛林制药股票老虎,拜玛林制药股票老虎国际,拜玛林制药行情,拜玛林制药股票行情,拜玛林制药股价,拜玛林制药股市,拜玛林制药股票价格,拜玛林制药股票交易,拜玛林制药股票购买,拜玛林制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"拜玛林制药(BMRN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供拜玛林制药(BMRN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}